JAMES M. MCCARTY
- Type
- Physician · Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases
- Where
- MADERA, CA
- NPI
- 1598777500
- Received
- $1,787,860 in 474 records, 2019 to 2025 ($877,181 general, $910,678 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 11 | $47,122 |
| 2025 | Research payment | 17 | $160,641 |
| 2024 | General payment | 1 | $955 |
| 2024 | Research payment | 19 | $102,987 |
| 2023 | General payment | 50 | $203,333 |
| 2023 | Research payment | 23 | $125,650 |
| 2022 | General payment | 88 | $218,015 |
| 2022 | Research payment | 47 | $215,687 |
| 2021 | General payment | 61 | $209,887 |
| 2021 | Research payment | 61 | $145,762 |
| 2020 | General payment | 35 | $155,067 |
| 2020 | Research payment | 50 | $159,950 |
| 2019 | General payment | 11 | $42,800 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Emergent BioSolutions Inc. | 460 | $1,700,383 | 2019–2025 |
| Bavarian Nordic A/S | 14 | $87,476 | 2023–2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 217 | $910,678 |
| Consulting Fee | 228 | $859,854 |
| Travel and Lodging | 21 | $14,163 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $2,668 |
| Food and Beverage | 5 | $495 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | Emergent BioSolutions Inc. | $14,612 | Consulting Fee | Cash or cash equivalent | ACAM2000 Drug, Smallpox | 2025 | |
| 2025-12-17 | Emergent BioSolutions Inc. | $4,987 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-11-19 | Emergent BioSolutions Inc. | $16,012 | Consulting Fee | Cash or cash equivalent | ACAM2000 Drug, Smallpox | 2025 | |
| 2025-11-19 | Emergent BioSolutions Inc. | $3,412 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-10-23 | Emergent BioSolutions Inc. | $9,887 | Consulting Fee | Cash or cash equivalent | ACAM2000 Drug, Smallpox | 2025 | |
| 2025-10-23 | Emergent BioSolutions Inc. | $8,837 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-09-17 | Emergent BioSolutions Inc. | $19,862 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-09-17 | Emergent BioSolutions Inc. | $2,012 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-08-20 | Emergent BioSolutions Inc. | $13,475 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-08-20 | Emergent BioSolutions Inc. | $3,937 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-07-16 | Emergent BioSolutions Inc. | $6,387 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-07-16 | Emergent BioSolutions Inc. | $3,587 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-06-18 | Emergent BioSolutions Inc. | $9,975 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-06-18 | Emergent BioSolutions Inc. | $437 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-06-04 | Emergent BioSolutions Inc. | $5,337 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2025 | |
| 2025-06-04 | Emergent BioSolutions Inc. | $4,558 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-04 | Emergent BioSolutions Inc. | $778 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-04-29 | Emergent BioSolutions Inc. | $1,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $277 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $158 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $78 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $76 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $32 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Emergent BioSolutions Inc. | $27 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-04-16 | Emergent BioSolutions Inc. | $18,375 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-03-19 | Emergent BioSolutions Inc. | $24,850 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-02-19 | Emergent BioSolutions Inc. | $16,537 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2025-01-15 | Emergent BioSolutions Inc. | $17,850 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2025 |
| 2024-12-18 | Emergent BioSolutions Inc. | $13,650 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-11-20 | Emergent BioSolutions Inc. | $11,287 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-10-16 | Emergent BioSolutions Inc. | $8,575 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-08-21 | Emergent BioSolutions Inc. | $2,887 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-08-21 | Emergent BioSolutions Inc. | $2,012 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-07-17 | Emergent BioSolutions Inc. | $10,500 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-07-17 | Emergent BioSolutions Inc. | $7,350 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-07-03 | Emergent BioSolutions Inc. | $10,762 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-07-03 | Emergent BioSolutions Inc. | $5,250 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-05-22 | Emergent BioSolutions Inc. | $8,400 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-05-22 | Emergent BioSolutions Inc. | $612 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-04-17 | Emergent BioSolutions Inc. | $1,312 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-04-17 | Emergent BioSolutions Inc. | $612 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-03-20 | Emergent BioSolutions Inc. | $5,250 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-03-20 | Emergent BioSolutions Inc. | $962 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-02-21 | Emergent BioSolutions Inc. | $6,125 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2024-02-21 | Emergent BioSolutions Inc. | $1,662 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-01-19 | Bavarian Nordic A/S | $955 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-01-17 | Emergent BioSolutions Inc. | $3,675 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2024 | |
| 2024-01-17 | Emergent BioSolutions Inc. | $2,100 | Research payment | Cash or cash equivalent | TEMBEXA Drug, Purine nucleosides | Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults (BCV-001) | 2024 |
| 2023-12-20 | Emergent BioSolutions Inc. | $2,712 | Research payment | Cash or cash equivalent | Tembexa Drug, Purine nucleosides | TMBX | 2023 |
| 2023-12-06 | Emergent BioSolutions Inc. | $4,550 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-11-15 | Emergent BioSolutions Inc. | $12,687 | Research payment | Cash or cash equivalent | Tembexa Drug, Purine nucleosides | TMBX | 2023 |
| 2023-11-08 | Emergent BioSolutions Inc. | $17,325 | Research payment | Cash or cash equivalent | Tembexa Drug, Purine nucleosides | TMBX | 2023 |
| 2023-11-02 | Emergent BioSolutions Inc. | $1,837 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-11-01 | Bavarian Nordic A/S | $6,300 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-26 | Bavarian Nordic A/S | $2,001 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-10-26 | Bavarian Nordic A/S | $105 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-10-26 | Bavarian Nordic A/S | $9 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-10-04 | Emergent BioSolutions Inc. | $11,987 | Research payment | Cash or cash equivalent | Tembexa Drug, Purine nucleosides | TMBX | 2023 |
| 2023-10-04 | Emergent BioSolutions Inc. | $2,275 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-10-01 | Bavarian Nordic A/S | $2,800 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-06 | Emergent BioSolutions Inc. | $8,487 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-09-01 | Bavarian Nordic A/S | $5,075 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-30 | Bavarian Nordic A/S | $20,737 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-30 | Bavarian Nordic A/S | $612 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-30 | Emergent BioSolutions Inc. | $612 | Research payment | Cash or cash equivalent | Tembexa Drug, Purine nucleosides | TMBX | 2023 |
| 2023-08-30 | Bavarian Nordic A/S | $612 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-23 | Emergent BioSolutions Inc. | $16,275 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-08-16 | Bavarian Nordic A/S | $20,912 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-16 | Bavarian Nordic A/S | $3,675 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-31 | Bavarian Nordic A/S | $12,512 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-07-05 | Emergent BioSolutions Inc. | $5,775 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-06-14 | Bavarian Nordic A/S | $11,168 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-31 | Emergent BioSolutions Inc. | $4,550 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $6,650 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $6,037 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $3,937 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-03 | Emergent BioSolutions Inc. | $3,937 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $3,325 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-05-03 | Emergent BioSolutions Inc. | $3,062 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $2,275 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $2,100 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $1,137 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-05-03 | Emergent BioSolutions Inc. | $1,137 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $8,050 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $5,250 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $4,550 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $4,112 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-04-05 | Emergent BioSolutions Inc. | $3,237 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $2,800 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $2,800 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $2,537 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $1,925 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-04-05 | Emergent BioSolutions Inc. | $700 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $87 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-04-05 | Emergent BioSolutions Inc. | $87 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $11,025 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $5,425 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $4,637 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $4,550 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $4,375 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $3,850 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $1,750 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $1,312 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $1,137 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-03-02 | Emergent BioSolutions Inc. | $700 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-03-02 | Emergent BioSolutions Inc. | $87 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-02-22 | Emergent BioSolutions Inc. | $9,100 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $4,812 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $2,975 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $2,362 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $2,275 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $2,012 | Research payment | Cash or cash equivalent | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $875 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-22 | Emergent BioSolutions Inc. | $700 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-02-22 | Emergent BioSolutions Inc. | $700 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-02-22 | Emergent BioSolutions Inc. | $87 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2023 | |
| 2023-02-02 | Emergent BioSolutions Inc. | $5,862 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2023 | |
| 2023-01-25 | Emergent BioSolutions Inc. | $3,587 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2023 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $10,587 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $6,037 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $4,900 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-14 | Emergent BioSolutions Inc. | $4,287 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $3,237 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $2,975 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $2,012 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-12-14 | Emergent BioSolutions Inc. | $1,575 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-14 | Emergent BioSolutions Inc. | $1,400 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-12-14 | Emergent BioSolutions Inc. | $525 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-14 | Emergent BioSolutions Inc. | $87 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-12-11 | Emergent BioSolutions Inc. | $8,137 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-12-11 | Emergent BioSolutions Inc. | $4,025 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-11 | Emergent BioSolutions Inc. | $3,937 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-11 | Emergent BioSolutions Inc. | $2,450 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-11 | Emergent BioSolutions Inc. | $1,750 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-12-11 | Emergent BioSolutions Inc. | $1,312 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-12-11 | Emergent BioSolutions Inc. | $962 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-12-11 | Emergent BioSolutions Inc. | $910 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-12-11 | Emergent BioSolutions Inc. | $815 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-12-11 | Emergent BioSolutions Inc. | $511 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-12-11 | Emergent BioSolutions Inc. | $87 | Research payment | Cash or cash equivalent | Chikungunya | EBSI-CV-317-004: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX03 | 2022 |
| 2022-12-11 | Emergent BioSolutions Inc. | $65 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-12-11 | Emergent BioSolutions Inc. | $59 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-11-23 | Emergent BioSolutions Inc. | $5,337 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-11-23 | Emergent BioSolutions Inc. | $3,937 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-11-07 | Emergent BioSolutions Inc. | $150 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-10-26 | Emergent BioSolutions Inc. | $6,212 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $5,687 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $5,687 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $5,250 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $3,850 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-10-26 | Emergent BioSolutions Inc. | $3,325 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $2,800 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-10-26 | Emergent BioSolutions Inc. | $1,925 | Research payment | Cash or cash equivalent | Chikungunya | EBSI-CV-317-002: A Phase 2 Open-Label Study to Assess the Safety and Immunogenicity of an Alum-Adjuvanted Chikungunya Vi | 2022 |
| 2022-10-26 | Emergent BioSolutions Inc. | $1,050 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-26 | Emergent BioSolutions Inc. | $262 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-10-05 | Emergent BioSolutions Inc. | $9,450 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-10-05 | Emergent BioSolutions Inc. | $5,425 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-10-05 | Emergent BioSolutions Inc. | $4,637 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-10-05 | Emergent BioSolutions Inc. | $3,587 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-10-05 | Emergent BioSolutions Inc. | $2,887 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-05 | Emergent BioSolutions Inc. | $2,800 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-10-05 | Emergent BioSolutions Inc. | $2,712 | Research payment | Cash or cash equivalent | Chikungunya | EBSI-CV-317-004: A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX03 | 2022 |
| 2022-10-05 | Emergent BioSolutions Inc. | $2,712 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-05 | Emergent BioSolutions Inc. | $612 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-10-05 | Emergent BioSolutions Inc. | $87 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-08-31 | Emergent BioSolutions Inc. | $6,650 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-08-31 | Emergent BioSolutions Inc. | $4,550 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-08-31 | Emergent BioSolutions Inc. | $3,587 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-08-31 | Emergent BioSolutions Inc. | $3,150 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-08-31 | Emergent BioSolutions Inc. | $2,537 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-08-31 | Emergent BioSolutions Inc. | $962 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-08-31 | Emergent BioSolutions Inc. | $175 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | Phase 4 Placebo Controlled Study to Assess the Safety and Immunogenicity of Vaxchora (Cholera Vaccine, Live, Oral) in In | 2022 |
| 2022-08-24 | Emergent BioSolutions Inc. | $10,500 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-08-24 | Emergent BioSolutions Inc. | $2,800 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $12,512 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $4,200 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $3,850 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $3,587 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-07-27 | Emergent BioSolutions Inc. | $3,500 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $3,237 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $3,062 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-07-27 | Emergent BioSolutions Inc. | $1,837 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-27 | Emergent BioSolutions Inc. | $612 | Research payment | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-07-27 | Emergent BioSolutions Inc. | $437 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Emergent BioSolutions Inc. | $5,485 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Emergent BioSolutions Inc. | $1,180 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Emergent BioSolutions Inc. | $358 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Emergent BioSolutions Inc. | $80 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-13 | Emergent BioSolutions Inc. | $45 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-06 | Emergent BioSolutions Inc. | $13,125 | Research payment | Cash or cash equivalent | Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001) | 2022 | |
| 2022-07-06 | Emergent BioSolutions Inc. | $5,862 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-06 | Emergent BioSolutions Inc. | $4,025 | Consulting Fee | Cash or cash equivalent | Vaxchora Drug, Cholera Vaccine | 2022 | |
| 2022-07-06 | Emergent BioSolutions Inc. | $3,850 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-07-06 | Emergent BioSolutions Inc. | $3,062 | Research payment | Cash or cash equivalent | Chikungunya | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 | 2022 |
| 2022-07-06 | Emergent BioSolutions Inc. | $2,100 | Consulting Fee | Cash or cash equivalent | Vivotif Drug, Salmonella Typhi | 2022 | |
| 2022-07-06 | Emergent BioSolutions Inc. | $1,532 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-07-06 | Emergent BioSolutions Inc. | $1,498 | Travel and Lodging | Cash or cash equivalent | 2022 |
The latest 200 records of 474.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Madera, CA, county Madera County, CA, state California; placed by its city name.
| Measure | Place (city or town) Madera, CA | County Madera County, CA | State California |
|---|---|---|---|
| Population B01003 | 67,831 | 160,940 | 39,287,377 |
| Population, 2020 census P1 | 66,224 | 156,255 | 39,538,223 |
| Median age B01002 | 30.4 | 34.6 | 37.9 |
| Under 18 B01001 | 30.8% | 27.1% | 22.0% |
| 65 and over B01001 | 9.6% | 14.4% | 15.7% |
| Households B11001 | 17,526 | 45,379 | 13,548,091 |
| Foreign born B05002 | 25.6% | 20.1% | 27.0% |
| Median household income B19013 | $63,933 | $76,627 | $99,122 |
| Median family income B19113 | $67,479 | $83,389 | $113,346 |
| Per capita income B19301 | $24,200 | $30,077 | $49,513 |
| Poverty rate B17001 | 25.6% | 19.2% | 12.0% |
| Unemployment rate B23025 | 12.6% | 10.1% | 6.6% |
| Civilian labor force B23025 | 29,997 | 69,012 | 20,068,466 |
| Mean commute (minutes) B08013 | 25.7 | 27.9 | 28.7 |
| Bachelor's degree or higher B15003 | 10.9% | 17.9% | 37.1% |
| Housing units B25001 | 18,562 | 51,015 | 14,644,735 |
| Owner-occupied B25003 | 54.7% | 67.5% | 55.9% |
| Renters B25003 | 45.3% | 32.5% | 44.1% |
| Median home value B25077 | $359,900 | $393,200 | $734,700 |
| Median gross rent B25064 | $1,353 | $1,390 | $2,036 |
| White, not Hispanic B03002 | 12.2% | 29.9% | 33.8% |
| Black B03002 | 2.9% | 2.4% | 5.2% |
| Hispanic or Latino B03002 | 81.1% | 60.9% | 40.2% |
| Asian B03002 | 1.3% | 2.4% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.4% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.
Comments